The global market for transcatheter treatment of the mitral and aortic valves is expected to increase from $4 billion to $8 billion in the next five years, but barriers exist. 

BioCardia’s AVANCE steerable introducer family has received FDA 510(k) clearance, the company announced May 8.

Research presented at the Heart Rhythm Society’s 40th annual scientific sessions in San Francisco May 7 suggests heart patients with implanted electronic devices know less about their therapies than they think they do.

The FDA has tied sodium-glucose cotransporter-2 inhibitors to 55 cases of a life-threatening form of gangrene in the past six years, according to a May 7 report in the Annals of Internal Medicine.

The prevalence of heart failure (HF) in the U.S. is increasing hand-in-hand with rising rates of diabetes and obesity, according to a recent analysis, and HF-related CVD death rates have followed suit—most notably in younger adults.

Heart disease is now the leading cause of maternal deaths in the U.S., the American College of Obstetricians and Gynecologists (ACOG) reported in early May, prompting the organization to publish a comprehensive guide on pregnancy and CVD.

Diabetic ketoacidosis is more prevalent in the U.S. than it is in Canada, according to a joint analysis from Harvard Medical School, the Cambridge Health Alliance, City University of New York and the University of Manitoba.

Researchers at the University of Georgia have uncovered 27 new metabolites associated with arterial stiffness, according to work published in the American Journal of Hypertension.